Loading organizations...
§ Private Profile · Mountain View, CA, USA
Life sciences company providing DNA sequencing platforms and services for genomic and clinical research, focused on whole genome sequencing.
Complete Genomics is a San Jose, California-based life sciences company that provides end-to-end DNA sequencing platforms, instruments, reagents, and software for various clinical and research applications. The organization operates a 78,979-square-foot headquarters that includes a newly opened 10,115-square-foot manufacturing facility to support the development of advanced diagnostics and therapeutics for complex conditions like cancer, obesity, and Alzheimer's. Operating at a significant global scale, the company has historically employed approximately 250 people, processed over 15,000 whole human genomes, and supported more than 10,900 scientific publications worldwide. Previously acquired by the Chinese genomics institution BGI in 2013, the enterprise recently entered a definitive agreement in 2026 to be acquired by Swiss Rockets AG under the incoming executive leadership of Vladimir Cmiljanovic. Complete Genomics was officially established and incorporated in 2005 by co-founders Cliff Reid and Rade Drmanac.
Complete Genomics has raised $84.0M across 2 funding rounds.
Complete Genomics has raised $84.0M in total across 2 funding rounds.
Complete Genomics has raised $84.0M in total across 2 funding rounds.
Complete Genomics's investors include Sands Capital, OrbiMed, Enterprise Partners Venture Capital, Highland Capital Management, OVP Venture Partners, Prospect Venture Partners.
Complete Genomics is a biotechnology company specializing in DNA sequencing platforms for human genome sequencing and analysis, offering end-to-end solutions including proprietary sequencing technology, informatics, and data management software.[1][2] It serves global researchers, healthcare providers, and labs by providing affordable, high-throughput sequencing services and instruments like the patented DNA nanoball-based DNBSEQ™ technology, solving the challenge of making routine whole human genome sequencing (hWGS) accessible and cost-effective.[4][7] As a wholly owned subsidiary of MGI (listed on the Shanghai Stock Exchange since 2022), the company has sequenced over 20,000 genomes, maintains nearly 600 patents, and supports around 3,000 global customers with ongoing expansions like a new U.S. manufacturing facility.[2][5][6]
Complete Genomics was founded in June 2005 in Silicon Valley (initially Sunnyvale, California) by Clifford Reid (initial chairman, president, and CEO), Radoje (Rade) Drmanac (co-founder and chief scientific officer), and John Curson.[1][2][4] Drmanac, a pioneer in genomics who proposed massively parallel sequencing in 1988, drove the vision post-Human Genome Project to enable affordable individual genome sequencing using innovations like sequencing by synthesis and combinatorial sequencing by ligation.[4][7] Early traction came swiftly: in February 2009, it sequenced its first human genome and submitted data to the National Center for Biotechnology Information; by November 2009, it published data for three genomes in *Science* and had sequenced 50 by year-end.[1][2] Pivotal moments included acquisition by BGI Group in March 2013 for $117 million (operating as a subsidiary under CEO Reid initially), relocation to San Jose, and integration into MGI in 2018, fueling over $1 billion in investments and growth to 200+ employees.[1][3][5][6]
Complete Genomics rides the genomics revolution, capitalizing on post-Human Genome Project (2003) advancements in next-generation sequencing (NGS) to democratize genetic data for precision medicine, disease research, and multi-omics applications.[4][7] Timing aligns with exploding demand for affordable hWGS amid falling sequencing costs, driven by AI-enhanced analysis, rising chronic disease burdens, and regulatory pushes for personalized healthcare. Market forces like China's genomics investments (via MGI/BGI) and U.S. biotech resurgence favor it, enabling hybrid global-U.S. operations that mitigate supply chain risks.[3][5][7] It influences the ecosystem by powering breakthroughs in biology and healthcare, training local genomics talent, and expanding lab automation to accelerate scientific discovery worldwide.[6][7]
Complete Genomics is poised to lead affordable NGS with DNBSEQ™ expansions, new U.S. manufacturing, and R&D in lab automation, targeting tens of millions in 2023+ investments for sequencers and customer centers.[5][7] Trends like AI-genomics integration, population-scale sequencing, and therapeutic applications will shape its path, potentially sequencing millions more genomes amid precision medicine growth. Its influence may evolve from service provider to ecosystem enabler, blending Silicon Valley innovation with global scale to make hWGS as routine as blood tests—reinforcing its founding mission to revolutionize accessible genomics.[4][7]
Complete Genomics has raised $84.0M across 2 funding rounds. Most recently, it raised $39.0M Series E in August 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2010 | $39M Series E | Sands Capital | OrbiMed, Enterprise Partners Venture Capital, Highland Capital Management, OVP Venture Partners, Prospect Venture Partners | Announced |
| Aug 1, 2009 | $45M Series D | — | OrbiMed, Enterprise Partners Venture Capital, Highland Capital Management, OVP Venture Partners, Prospect Venture Partners | Announced |